Hitting cancer early: AstraZeneca's bid to outmaneuver rivals

LONDON (Reuters) - AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit.

from Reuters: Health News https://ift.tt/2MNrghS
via IFTTT